This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
TAS3681, a new type of androgen receptor antagonist, disrupts aberrant AR signaling that drives tumor resistance to AR-targeted therapies by downregulating full-length and splice variant AR. (December 2016)
Record Type:
Journal Article
Title:
TAS3681, a new type of androgen receptor antagonist, disrupts aberrant AR signaling that drives tumor resistance to AR-targeted therapies by downregulating full-length and splice variant AR. (December 2016)
Main Title:
TAS3681, a new type of androgen receptor antagonist, disrupts aberrant AR signaling that drives tumor resistance to AR-targeted therapies by downregulating full-length and splice variant AR